Iressa has expanded health insurance coverage

Insurance coverage for Iressa (gefitinib), a targeted oral anti-cancer drug, has been expanded to patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase) in the second-line therapy from October 1, according to AstraZeneca Korea.

Iressa acts by inhibiting the tyrosine kinase enzyme ...